Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.55
BDSI's Cash-to-Debt is ranked lower than
83% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. BDSI: 0.55 )
Ranked among companies with meaningful Cash-to-Debt only.
BDSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 5.11 Max: No Debt
Current: 0.55
Equity-to-Asset 0.21
BDSI's Equity-to-Asset is ranked lower than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BDSI: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
BDSI' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.52  Med: 0.35 Max: 0.87
Current: 0.21
-2.52
0.87
Debt-to-Equity 1.89
BDSI's Debt-to-Equity is ranked lower than
89% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. BDSI: 1.89 )
Ranked among companies with meaningful Debt-to-Equity only.
BDSI' s Debt-to-Equity Range Over the Past 10 Years
Min: -23.62  Med: 0.21 Max: 4.37
Current: 1.89
-23.62
4.37
Debt-to-EBITDA -1.40
BDSI's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. BDSI: -1.40 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BDSI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.4  Med: -0.33 Max: 0
Current: -1.4
-1.4
0
Piotroski F-Score: 3
Altman Z-Score: -2.85
Beneish M-Score: 2.24
WACC vs ROIC
9.54%
-201.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -56.79
BDSI's Operating Margin % is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. BDSI: -56.79 )
Ranked among companies with meaningful Operating Margin % only.
BDSI' s Operating Margin % Range Over the Past 10 Years
Min: -10722.77  Med: -445.27 Max: 63.88
Current: -56.79
-10722.77
63.88
Net Margin % 10.40
BDSI's Net Margin % is ranked higher than
74% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. BDSI: 10.40 )
Ranked among companies with meaningful Net Margin % only.
BDSI' s Net Margin % Range Over the Past 10 Years
Min: -12468.81  Med: -260.99 Max: 6552.47
Current: 10.4
-12468.81
6552.47
ROE % 45.83
BDSI's ROE % is ranked higher than
91% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. BDSI: 45.83 )
Ranked among companies with meaningful ROE % only.
BDSI' s ROE % Range Over the Past 10 Years
Min: -957  Med: -202.37 Max: 45.83
Current: 45.83
-957
45.83
ROA % 6.75
BDSI's ROA % is ranked higher than
80% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. BDSI: 6.75 )
Ranked among companies with meaningful ROA % only.
BDSI' s ROA % Range Over the Past 10 Years
Min: -133.16  Med: -60.42 Max: 124.67
Current: 6.75
-133.16
124.67
ROC (Joel Greenblatt) % -700.75
BDSI's ROC (Joel Greenblatt) % is ranked lower than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. BDSI: -700.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BDSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10265.14  Med: -991.94 Max: 2073.85
Current: -700.75
-10265.14
2073.85
3-Year Revenue Growth Rate -1.00
BDSI's 3-Year Revenue Growth Rate is ranked lower than
58% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BDSI: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BDSI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 12.85 Max: 418.2
Current: -1
-64.8
418.2
3-Year EBITDA Growth Rate -7.10
BDSI's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BDSI: -7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BDSI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: -1.85 Max: 53.4
Current: -7.1
-47.3
53.4
3-Year EPS without NRI Growth Rate -6.10
BDSI's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. BDSI: -6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BDSI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.1  Med: 16.8 Max: 68.4
Current: -6.1
-68.1
68.4
GuruFocus has detected 3 Warning Signs with BioDelivery Sciences International Inc BDSI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BDSI's 30-Y Financials

Financials (Next Earnings Date: 2018-03-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BDSI Guru Trades in Q4 2016

Jim Simons Sold Out
Chuck Royce 551,200 sh (-64.28%)
» More
Q1 2017

BDSI Guru Trades in Q1 2017

Jim Simons 152,800 sh (New)
Chuck Royce Sold Out
» More
Q2 2017

BDSI Guru Trades in Q2 2017

Jim Simons 490,700 sh (+221.14%)
» More
Q3 2017

BDSI Guru Trades in Q3 2017

Chuck Royce 1,292,800 sh (New)
Jim Simons 585,200 sh (+19.26%)
» More
» Details

Insider Trades

Latest Guru Trades with BDSI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ASX:BNO, NAS:NBRV, NAS:VBLT, TPE:4142, NAS:REPH, LSE:IMM, WAR:SLV, NAS:OVID, XTER:B8F, NAS:CGEN, XTER:CNWK, NAS:OCUL, OSTO:MVIR B, TSX:FRX, XKRX:046210, OTCPK:RASP, NAS:CKPT, NAS:COOL, LSE:BVXP, XTAE:RDHL » details
Traded in other countries:BD5.Germany,
Headquarter Location:USA
BioDelivery Sciences International Inc is a specialty pharmaceutical company. It is developing and commercializing new applications of approved therapeutics to address important unmet medical needs.

BioDelivery Sciences International is a biotechnology company that specializes in pain management and addiction medicine. The company's products and candidates are based on BioErodible MucoAdhesive, a proprietary B drug delivery technology. BEMA is a small, erodible polymer film for application to the buccal mucosa, which is used in approved products and candidates such as ONSOLIS (fentanyl buccal soluble film) for treating cancer pain; BUNAVAIL (buprenorphine and naloxone buccal film) to treat opioid dependence; and product candidate BELBUCA (formerly referred to as BEMA Buprenorphine), which aims to treat chronic pain.

Top Ranked Articles about BioDelivery Sciences International Inc

Market Trends Toward New Normal in OneMain, Versum Materials, BioDelivery Sciences International, Microsemi, Pattern Energy Group, and Omega Protein — Emerging Consolidated Expectations, Analyst Ratings
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment
BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Ratios

vs
industry
vs
history
PE Ratio 22.00
BDSI's PE Ratio is ranked lower than
96% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. BDSI: 22.00 )
Ranked among companies with meaningful PE Ratio only.
BDSI' s PE Ratio Range Over the Past 10 Years
Min: 0.88  Med: 6.32 Max: 335
Current: 22
0.88
335
PE Ratio without NRI 22.00
BDSI's PE Ratio without NRI is ranked lower than
95% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. BDSI: 22.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
BDSI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.88  Med: 6.32 Max: 335
Current: 22
0.88
335
PB Ratio 6.51
BDSI's PB Ratio is ranked lower than
67% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BDSI: 6.51 )
Ranked among companies with meaningful PB Ratio only.
BDSI' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 6.83 Max: 354.74
Current: 6.51
2.3
354.74
PS Ratio 2.28
BDSI's PS Ratio is ranked higher than
77% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. BDSI: 2.28 )
Ranked among companies with meaningful PS Ratio only.
BDSI' s PS Ratio Range Over the Past 10 Years
Min: 0.89  Med: 14.05 Max: 1156.67
Current: 2.28
0.89
1156.67
EV-to-EBIT -4.58
BDSI's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. BDSI: -4.58 )
Ranked among companies with meaningful EV-to-EBIT only.
BDSI' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.8  Med: -3.3 Max: 32.5
Current: -4.58
-58.8
32.5
EV-to-EBITDA -5.46
BDSI's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. BDSI: -5.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDSI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.3  Med: -3.5 Max: 23
Current: -5.46
-118.3
23
EV-to-Revenue 2.60
BDSI's EV-to-Revenue is ranked higher than
79% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. BDSI: 2.60 )
Ranked among companies with meaningful EV-to-Revenue only.
BDSI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 13.4 Max: 1067
Current: 2.6
0.4
1067
Current Ratio 1.28
BDSI's Current Ratio is ranked lower than
82% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BDSI: 1.28 )
Ranked among companies with meaningful Current Ratio only.
BDSI' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.21 Max: 6.96
Current: 1.28
0.03
6.96
Quick Ratio 1.07
BDSI's Quick Ratio is ranked lower than
81% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. BDSI: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
BDSI' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.18 Max: 6.96
Current: 1.07
0.03
6.96
Days Inventory 125.90
BDSI's Days Inventory is ranked higher than
50% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. BDSI: 125.90 )
Ranked among companies with meaningful Days Inventory only.
BDSI' s Days Inventory Range Over the Past 10 Years
Min: 67.55  Med: 96.06 Max: 125.9
Current: 125.9
67.55
125.9
Days Sales Outstanding 73.75
BDSI's Days Sales Outstanding is ranked higher than
54% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. BDSI: 73.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDSI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.49  Med: 48.65 Max: 650.89
Current: 73.75
3.49
650.89
Days Payable 256.65
BDSI's Days Payable is ranked higher than
87% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. BDSI: 256.65 )
Ranked among companies with meaningful Days Payable only.
BDSI' s Days Payable Range Over the Past 10 Years
Min: 256.65  Med: 564.49 Max: 1275.75
Current: 256.65
256.65
1275.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.30
BDSI's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BDSI: -12.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDSI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.1  Med: -18 Max: -8
Current: -12.3
-38.1
-8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.16
BDSI's Price-to-Median-PS-Value is ranked higher than
91% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BDSI: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BDSI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: 83.5
Current: 0.16
0.07
83.5
Earnings Yield (Greenblatt) % -21.84
BDSI's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. BDSI: -21.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BDSI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -256.7  Med: -24.5 Max: 148
Current: -21.84
-256.7
148

More Statistics

Revenue (TTM) (Mil) $53.41
EPS (TTM) $ 0.10
Beta1.13
Short Percentage of Float2.58%
52-Week Range $1.50 - 3.60
Shares Outstanding (Mil)55.88

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 58 50 70 109
EPS ($) 0.20 -0.57 -0.28 0.30
EPS without NRI ($) 0.20 -0.57 -0.28 0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}